NCT00203177View on ClinicalTrials.gov

Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.

PHASE3CompletedINTERVENTIONAL
Enrollment

254

Participants

Timeline

Start Date

October 31, 2001

Primary Completion Date

December 31, 2006

Conditions
Parkinson's Disease
Interventions
DRUG

rasagiline mesylate

0.5 rasagiline mesylate

DRUG

rasagiline mesylate 1.0 mg

1.0 mg rasagiline mesylate

Trial Locations (8)

11040

Long Island Jewish Medical Center, New Hyde Park

14642

University of Rochester, Rochester

19107

Pennsylvania Hospital, Philadelphia

30329

Emory University, Atlanta

60612

Rush - Presbyterian St. Luke's Medical Center, Chicago

68131

Creighton University, Omaha

93720

Margolin Brain Institute, Fresno

H2w1T8

CHUM-Hotel-Dieu, Montreal

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT00203177 - Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy. | Biotech Hunter | Biotech Hunter